SAN DIEGO, May 24 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today it was issued two patents from the U.S. Patent and Trademark Office, including U.S. Patent No. 6,891,154, "Amino Acid Sequence Pattern Matching" and No. 6,893,822, "Enzymatic modification of a nucleic acid-synthetic binding unit conjugate." Nanogen's growing portfolio of 128 U.S. patents now includes intellectual property related to novel biomarker discovery technology and methods of isolating nucleic acids on a microarray. "The technology that these patents cover can improve our ability to find appropriate biomarkers and can improve the use of multiplexing in diagnostics, helping us to bring valuable diagnostic solutions to the market," said Howard C. Birndorf, Nanogen's chairman of the board and chief executive officer. "The amino acid matching technology has been used internally to expedite protein biomarker discovery, providing Nanogen the potential to identify novel biomarkers of disease for future diagnostic product development. In addition, our SBU technology promotes specificity and flexibility in the use of our microarrays." The '154 patent relates to software designed for amino acid sequencing pattern matching and determining the number of possible sequences consistent with the molecular weight of the amino acid. The essential task of determining the amino acid sequence of an unknown protein depends on sorting through a large amount of data generated by a mass spectrometer, which can be time consuming and difficult. In addition, variables such as noise filtration, offsets in samples and multiple sample preparation methods can result in unacceptable readings from several samples. This sequence pattern matching software is designed to provide a superior method for analyzing a large amount of data to identify unique amino acid sequences quickly, which is key to proteomic biomarker discovery. The software was developed by SynX Pharma, a Nanogen subsidiary. The '822 patent relates to methods using novel synthetic binding units (SBUs) with very high specificity and sensitivity, linked to nucleic acids as primers in a PCR or other nucleic acid amplification and detection reaction. The SBUs only bind to a very specific complement SBU, which may be on a microarray chip. The SBU can act similarly to the commonly-used biotin/strepavidin binding pair but many different SBU pairs can be synthesized. In a multiplex amplification, unique primers can be paired with unique SBUs so that upon detection on a microarray, the amplified products array themselves automatically to bind with a complementary SBU attached to the array. Alternatively a SBU can be used as a label to detect a specific nucleic acid. The '822 patent adds to a family of technologies that allows for novel methods of active construction of arrays of immobilized nucleic acids utilizing prefabricated arrays of SBUs. About Nanogen, Inc. Nanogen's advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop diagnostic tests for variety of diseases. Nanogen also offers a broad portfolio of patented nucleic acids chemistries and molecular tools that accelerate genomic analysis and are compatible with many systems. The SynX subsidiary offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website at www.nanogen.com. Nanogen Forward-Looking Statement This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.